GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Return-on-Tangible-Equity

CVRx (CVRX) Return-on-Tangible-Equity : -124.81% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CVRx Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CVRx's annualized net income for the quarter that ended in Mar. 2024 was $-88.74 Mil. CVRx's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $71.10 Mil. Therefore, CVRx's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -124.81%.

The historical rank and industry rank for CVRx's Return-on-Tangible-Equity or its related term are showing as below:

CVRX' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -62.72   Med: -38.49   Max: -32.47
Current: -62.72

During the past 5 years, CVRx's highest Return-on-Tangible-Equity was -32.47%. The lowest was -62.72%. And the median was -38.49%.

CVRX's Return-on-Tangible-Equity is ranked worse than
77% of 761 companies
in the Medical Devices & Instruments industry
Industry Median: 1.4 vs CVRX: -62.72

CVRx Return-on-Tangible-Equity Historical Data

The historical data trend for CVRx's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Return-on-Tangible-Equity Chart

CVRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
- - - -32.47 -44.51

CVRx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.57 -49.16 -41.72 -46.17 -124.81

Competitive Comparison of CVRx's Return-on-Tangible-Equity

For the Medical Devices subindustry, CVRx's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CVRx's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CVRx's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where CVRx's Return-on-Tangible-Equity falls into.



CVRx Return-on-Tangible-Equity Calculation

CVRx's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-41.199/( (109.18+75.947 )/ 2 )
=-41.199/92.5635
=-44.51 %

CVRx's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-88.744/( (75.947+66.261)/ 2 )
=-88.744/71.104
=-124.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


CVRx  (NAS:CVRX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


CVRx Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of CVRx's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CVRx (CVRX) Business Description

Traded in Other Exchanges
N/A
Address
9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Executives
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro officer: Chief Marketing Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes director 2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain director C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer officer: SVP, U.S. Sales 9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P 10 percent owner
Nea Partners 10 L P 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo director 100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim officer: Chief Financial Officer 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall officer: Chief Strategy Officer and Sec 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding officer: VP of Reg. Affairs and QA 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle officer: VP of Global Clinical Research 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared director, officer: Chief Executive Officer 9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445